Department of Internal Medicine, University of Iowa, Iowa City, IA, USA.
Brain Res. 2010 Jun 18;1338:112-21. doi: 10.1016/j.brainres.2010.03.038. Epub 2010 Mar 20.
RNA interference (RNAi) is a process of sequence-specific gene silencing and serves as a powerful molecular tool to manipulate gene expression in vitro and in vivo. RNAi technologies have been applied to study gene function and validate drug targets. Researchers are investigating RNAi-based compounds as novel therapeutics to treat a variety of human diseases that are currently lacking sufficient treatment. To date, numerous studies support that RNAi therapeutics can improve disease phenotypes in various rodent models of human disease. Here, we focus on the development of RNAi-based therapies aimed at treating neurological disorders for which reduction of mutant or toxic gene expression may provide clinical benefit. We review RNAi-based gene-silencing strategies, proof-of-concept studies testing therapeutic RNAi for CNS disorders, and highlight the most recent research aimed at transitioning RNAi-based therapeutics toward clinical trials.
RNA 干扰(RNAi)是一种序列特异性基因沉默的过程,是一种在体外和体内操纵基因表达的强大分子工具。RNAi 技术已被应用于研究基因功能和验证药物靶点。研究人员正在研究基于 RNAi 的化合物作为新型治疗剂,以治疗目前治疗方法不足的多种人类疾病。迄今为止,大量研究表明,RNAi 治疗剂可改善各种人类疾病的啮齿动物模型中的疾病表型。在这里,我们专注于开发针对治疗神经系统疾病的基于 RNAi 的疗法,这些疾病可能通过降低突变或毒性基因的表达而获得临床益处。我们回顾了基于 RNAi 的基因沉默策略、针对中枢神经系统疾病的治疗性 RNAi 的概念验证研究,并强调了最近旨在将基于 RNAi 的治疗剂推向临床试验的研究。